US Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Insight
US non-alcoholic steatohepatitis (NASH) biomarkers market size is growing at a 12.60% CAGR, driven by rising prevalence of liver diseases, increasing demand for non-invasive diagnostic solutions, and growing focus on early disease detection and personalized medicine.
US Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Insights Forecasts to 2035
- The US Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size Was Estimated at USD 1,140.0 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 12.60% from 2025 to 2035
- The US Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market Size is Expected to Reach USD 3,760.0 Million by 2035
Notable Insights for US Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market
- By type, serum biomarkers dominated the market, generating approximately USD 520.0 Million in revenue in 2024 due to their widespread use in non-invasive liver disease diagnosis.
- By application, disease diagnosis is expected to witness the fastest growth, supported by increasing need for early and accurate detection of NASH.
- Approximately 74% of demand is driven by hospitals and diagnostic laboratories, while nearly 59% growth is supported by advancements in biomarker discovery, imaging technologies, and increasing clinical trials for NASH therapies. Additionally, rising awareness and screening initiatives are supporting market expansion.
- Growing prevalence of obesity and metabolic disorders, increasing demand for non-invasive testing, and rising R&D investments in liver disease diagnostics are driving market growth.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the US Non-Alcoholic Steatohepatitis (NASH) Biomarkers market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in US Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market
- Labcorp (Laboratory Corporation of America Holdings)
- Quest Diagnostics Incorporated
- Thermo Fisher Scientific Inc.
- F. Hoffmann-La Roche Ltd
- Abbott Laboratories
- Siemens Healthineers AG
- Bio-Rad Laboratories, Inc.
- Genfit S.A.
- Others
Recent Developments:
- In November 2025, Thermo Fisher Scientific Inc. expanded its biomarker research solutions targeting liver diseases including NASH.
- In May 2024, Quest Diagnostics Incorporated enhanced its diagnostic testing portfolio with advanced liver disease biomarker panels.
Market Segmentation:
US Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market, By Type
- Serum Biomarkers
- Imaging Biomarkers
- Genetic Biomarkers
US Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market, By Application
- Disease Diagnosis
- Drug Development
- Research
US Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market, By End User
- Hospitals
- Diagnostic Laboratories
- Research Institutes
Expert Views:
The US NASH Biomarkers Market is expected to witness strong growth, driven by increasing prevalence of liver diseases and demand for early diagnosis. Experts highlight that advancements in non-invasive diagnostics, biomarker accuracy, and integration with AI-driven healthcare solutions will play a key role in shaping future market trends.